{"id":"W823422456","doi":"10.1056/nejmoa1501646","title":"A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis","year":2015,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":298,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"","keywords":"Medicine; Psoriasis; Placebo; Adalimumab; Internal medicine; Clinical endpoint; Randomization; Gastroenterology; Plaque psoriasis; Surgery; Randomized controlled trial; Dermatology; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002713159,0.001995353,0.002464072,0.0005116247,0.0004089855,0.001027899,0.0009482535,0.001562195,0.007997421],"category_scores_gemma":[0.001809319,0.0007474383,0.001451675,0.0003527048,0.001050564,0.001062972,0.0003979969,0.003181386,0.001211321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006211657,"about_ca_system_score_gemma":0.001051819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004999936,"about_ca_topic_score_gemma":0.001015988,"domain_scores_codex":[0.9991284,0.0005174822,0.00004025878,0.0001451952,0.00007079983,0.00009792549],"domain_scores_gemma":[0.9991086,0.0002819479,0.0001905075,0.00006684483,0.0000503864,0.0003015752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9692349,0.008831113,0.0003686859,0.000545147,0.0004954629,0.00004613405,0.0000524475,0.0002741527,0.004612542,0.0000898077,0.0007659907,0.01468369],"study_design_scores_gemma":[0.9609197,0.03746318,0.0006622868,0.00001613761,0.0001426972,0.00002922196,0.000008255714,0.000182779,0.000239801,0.00006446486,0.0002661879,0.000005392025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854771,0.006095119,0.0007514547,0.000897902,0.0005485275,0.003034383,0.0008893784,0.0001483821,0.002157713],"genre_scores_gemma":[0.9849555,0.002964396,0.00196121,0.001397216,0.0005854645,0.004104026,0.001142008,0.00003504158,0.002855161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007997421,"threshold_uncertainty_score":0.02675402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07114551676151244,"score_gpt":0.3284398490840408,"score_spread":0.2572943323225284,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}